Update on new antivirals under development for the treatment of double-stranded DNA virus infections

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 610-619

  Dropulic, L K ^a   Cohen, J I ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BAVITUXIMAB; BENZIMIDAVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CLEVUDINE; DNA POLYMERASE; DOUBLE STRANDED DNA; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VALACICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; DNA VIRUS; VIRUS DNA;

ADENOVIRUS; ANTIVIRAL ACTIVITY; CELL CULTURE; DNA SYNTHESIS; DNA VIRUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HEPATITIS B VIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; ORTHOPOXVIRUS; PAPILLOMA VIRUS; POLYOMA VIRUS; POXVIRUS; PRIORITY JOURNAL; REVIEW; VACCINIA; VIRUS INFECTION; VIRUS REPLICATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); CONFORMATION; DISEASE MODEL; DNA VIRUS INFECTIONS; DRUG DESIGN; DRUG EFFECTS; GENETICS; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DNA VIRUS INFECTIONS; DNA VIRUSES; DNA, VIRAL; DRUG DESIGN; HUMANS; NUCLEIC ACID CONFORMATION; TREATMENT OUTCOME;

EID: 77958487269     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.178     Document Type: Review

References (55)

1. Beadle, J.R. et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46, 2381-2386 (2002).
2. Quenelle, D.C., Collins, D.J., Wan, W.B., Beadle, J.R., Hostetler, K.Y. & Kern, E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48, 404-412 (2004).
3. Buller, R.M., Owens, G., Schriewer, J., Melman, L., Beadle, J.R. & Hostetler, K.Y. Efcacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318, 474-481 (2004).
4. Adams, M.M., Rice, A.D. & Moyer, R.W. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J. Virol. 81, 11084-11095 (2007).
5. Bidanset, D.J., Beadle, J.R., Wan, W.B., Hostetler, K.Y. & Kern, E.R. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J. Infect. Dis. 190, 499-503 (2004).
6. Toth, K. et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc. Natl. Acad. Sci. USA 105, 7293-7297 (2008).
7. Robertson, A. et al. Safety and pharmacokinetic analysis of CMX001: results from a FTIH dose escalation study (CMX001-102). IDSA Annual Meeting, October 2009.
8. Centers for Disease Control and Prevention. Progressive vaccinia in a military smallpox vaccinee-United States, 2009. Morb. Mortal. Wkly. Rep. 58, 532-536 (2009).
9. Crute, J.J. et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 8, 386-391 (2002).
10. Kleymann, G. et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8, 392-398 (2002).
11. Chono, K. et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J. Antimicrob. Chemother. 65, 1753-1741 (2010).
12. Betz, U.A., Fischer, R., Kleymann, G., Hendrix, M. & Rübsamen-Waigmann, H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 46, 1766-1772 (2002).
13. Biswas, S., Swift, M. & Field, H.J. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1. Antivir. Chem. Chemother. 18, 13-23 (2007). (Pubitemid 46426934)
14. Baumeister, J., Fischer, R., Eckenberg, P. , Henninger, K., Ruebsamen-Waigmann, H. & Kleymann, G. Superior efcacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir. Chem. Chemother. 18, 35-48 (2007).
15. Kaufman, H.E. et al. Efcacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. J. Ocul. Pharmacol. Ther. 24, 34-42 (2008).
16. Katsumata, K., Chono, K., Kontani, T., Sudo, K., Shimizu, Y., Suzuki, H. Efect of acute oral treatment with ASP2151 or valacyclovir (VACV) against cutaneous infection with herpes simplex virus (HSV) type 1 in mice [abstr V-1742]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 12-15 September 2009.
17. McGuigan, C. et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J. Antimicrob. Chemother. 60, 1316-1330 (2007).
18. Matson, M., Pentikis, H., Boehlecke, B., Wenzel, E., Henson, G., Morris, A. A study of the safety and pharmacokinetics of multiple ascending doses of FV-100 in healthy subjects [abstr]. Antiviral Res. 82, A49 (2009).
19. Biron, K.K. et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46, 2365-2372 (2002).
20. Williams, S.L. et al. In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47, 2186-2192 (2003).
21. Chou, S., Marousek, G.I., Senters, A.E., Davis, M.G. & Biron, K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78, 7124-7130 (2004).
22. Koszalka, G.W. et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 46, 2373-2380 (2002).
23. Kern, E.R. et al. Activities of benzimidazole D-and L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob. Agents Chemother. 48, 1749-1755 (2004).
24. Lalezari, J.P. et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodefciency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46, 2969-2976 (2002).
25. Wang, L.H., Peck, R.W., Yin, Y., Allanson, J., Wiggs, R. & Wire, M.B. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodefciency virus-infected subjects. Antimicrob. Agents Chemother. 47, 1334-1342 (2003).
26. Winston, D.J. et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111, 5403-5410 (2008).
27. Yang, G. et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79, 13139-13149 (2005).
28. Berhanu, A. et al. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob. Agents Chemother. 53, 4999-5009 (2009).
29. Quenelle, D.C. et al. Synergistic efcacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51, 4118-4124 (2007).
30. Grosenbach, D.W. et al. Efcacy of ST-246 versus lethal poxvirus challenge in immunodefcient mice. Proc. Natl. Acad. Sci. USA 107, 838-843 (2010).
31. Sbrana, E. et al. Efcacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76, 768-773 (2007).
32. Huggins, J. et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53, 2620-2625 (2009).
33. Jordan, R. et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 52, 1721-1727 (2008).
34. Jordan, R. et al. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob. Agents Chemother. 54, 2560-2566 (2010).
35. Vora, S. et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 46, 1555-1561 (2008).
36. Wolfgang, G.H. et al. GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions. Antimicrob. Agents Chemother. 53, 2777-2784 (2009).
37. Chu, C.K. et al. Use of 2'-fuoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. 39, 979-981 (1995).
38. Ono, S.K. et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107, 449-455 (2001).
39. Chu, C.K. et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir. Ther. (Lond.) 3, 113-121 (1998).
40. Peek, S.F. et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fuoro-5-methyl-β, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33, 254-266 (2001).
41. Korba, B.E., Furman, P.A. & Otto, M.J. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev. Anti. Infect. Ther. 4, 549-561 (2006). (Pubitemid 44523935)
42. Seok, J.I. et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 49, 2080-2086 (2009).
43. Korba, B.E., Schinazi, R.F., Cote, P. , Tennant, B.C. & Gerin, J.L. Efect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. 44, 1757-1760 (2000).
44. Menne, S. et al. Antiviral efects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 52, 3617-3632 (2008).
45. Dienstag, J.L. Hepatitis B virus infection. N. Engl. J. Med. 359, 1486-1500 (2008).
46. Gish, R.G. et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J. Hepatol. 43, 60-66 (2005).
47. Lim, S.G. et al.; Emtricitabine FTCB-301 Study Group. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch. Intern. Med. 166, 49-56 (2006).
48. Soares, M.M., King, S.W. & Thorpe, P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 14, 1357-1362 (2008).
49. Wolf, M.C. et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. USA. 107, 3157-3162 (2010).
50. Huggins, J.W., Baker, R.O., Beadle, J.R., Hostetler, K.Y. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. Antiviral Res. 53, 104 (2002).
51. Kern, E.R. et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46, 991-995 (2002).
52. Williams-Aziz, S.L. et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49, 3724-3733 (2005).
53. Randhawa, P. , Farasati, N.A., Shapiro, R. & Hostetler, K.Y. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob. Agents Chemother. 50, 1564-1566 (2006).
54. Hartline, C.B. et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J. Infect. Dis. 191, 396-399 (2005).
55. Hostetler, K.Y., Rought, S., Aldern, K.A., Trahan, J., Beadle, J.R. & Corbeil, J. Enhanced antiproliferative efects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Mol. Cancer Ther. 5, 156-159 (2006).